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Recent reports have described an increasing incidence of community-associated
methicillin-resistant Staphylococcus aureus (CA-MRSA); this group differs from
the health care-associated (HA) MRSA and has become a major concern world-
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Purpose: Community-associated methicillin resistant Staphylococcus aureus (CA-
MRSA) infections are increasing. Although gentamicin (GEN) is usually susceptible
against CA-MRSA, GEN is rarely considered for treatment as monotherapy. We
employed an in vitro pharmacodynamic model (IVPDM) to compare efficacies of
GEN against CA-MRSA with two dosing regimens [thrice-daily (TD), once-daily
(OD)]. Materials and Methods: Using two strains of CA-MRSA, we adopted
IVPDM comprised of two-compartments with a surface-to-volume ratio of 5.34 cm
-1.
GEN regimens were simulated with human pharmacokinetic data of TD and OD.
Experiments were performed over 48 hours in triplicate for each strain and dosing
regimen. Results: MICs of GEN for YSSA1 and YSSA15 were 1 and 2 mg/L,
respectively. In OD, indices of peak/MIC were > 8.6 at least, in contrast to < 6.4 in
TD. A ≥ 3-log10 reduction in CFU/mL was demonstrated prior to 4 hours in TD and
OD, and continued until 8 hours for both strains. However, reductions in the colony
counts at 24 and 48 hours were significantly larger for OD compared to TD in both
strains (p < 0.001). During TD, resistance developed in YSSA1 and small colony
variants (SCVs) were documented in YSSA15. No resistance or SCVs were
observed during OD in both strains. Conclusion: TD and OD showed the same
killing slopes until 8 hours. After the 24 hours of experiments, OD of GEN would be
advantageous not only in having more reductions in colony counts, but also
suppressing the development of resistance or SCVs for 48 hours.
Key Words: Methicillin-Resistant Staphylococcus aureus, gentamicin, pharma-
codynamics, once-daily treatment
Received: August 5, 2009
Revised: October 4, 2009
Accepted: November 4, 2009
Corresponding author: Dr. Dong-Gun Lee,
Department of Internal Medicine, 
College of Medicine, 
The Catholic University of Korea, 
505 Banpo-dong, Seocho-gu, 
Seoul 137-701, Korea.
Tel: 82-2-2258-6003, Fax: 82-2-535-2494
E-mail: symonlee@catholic.ac.kr
∙The authors have no financial conflicts of
interest.
© Copyright:
Yonsei University College of Medicine 2010
This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
INTRODUCTIONwide.
1,2 Most cases of CA-MRSA have been associated
with the absence of multi-drug resistance in contrast to HA-
MRSA cases. A common strategy for treating serious
MRSA infection is to use glycopeptide with or without
aminoglycosides.
3-5 However, gentamicin (GEN) is rarely
considered for the treatment of CA-MRSA in combination
or monotherapy due to questions of efficacy based on dis-
cordant in vitro studies, lack of supporting clinical data,
and risk of the development of nephrotoxicity and resis-
tance; although it is usually susceptible against CA-
MRSA.
2,6-9 Another recently additional concern is the de-
velopment of small colony variants (SCVs)-subpopulation
with reduced susceptibility-with incomplete inhibitory con-
centrations of GEN, which may be responsible for recur-
rence or persistence of infection.
10-12
It is needed to ascertain whether characteristics of tradi-
tional thrice-daily (TD) or once-daily (OD) administration
of GEN is working against CA-MRSA as reported in cases
of gram-negative rods infection.
13,14
In this study, we have tried to evaluate the efficacy and
to monitor the development of resistance or SCVs during
TD administration of GEN in an in vitro pharmacodynamic
model (IVPDM). In addition, we compared the efficacy of
TD to OD dosing of GEN with considering optimal phar-
macodynamic indices.
Bacterial strains
Two prototypes of GEN susceptible CA-MRSA strains,
previously reported from our laboratory, were used in this
study. One (YSSA1) is the multilocus sequence type (ST)
72-staphylococcal chromosome cassette mec (SCCmec)
type IVA-spa t324-group I agr without Panton-Valentine
leukocidin (PVL) gene, which is considered representative
of predominant CA-MRSA clonal type in Korea. The other
(YSSA15) is the USA 300 like strain characterized by
ST8-SCCmec type IV-spa type t008-group I agr and PVL
positive.
15,16
Susceptibility testing, antibiotics, and media for 
susceptibility testing, model simulations and 
pharmacodynamic analyses
Broth microdilution MICs were performed in accordance
with the Clinical and Laboratory Standards Institute
Guidelines.
17 GEN was purchased (Sigma Chemical, St.
Louis, MO, USA). Its solution stock, with a concentration
of 1 mg/mL, was frozen at -70˚C. Cation-adjusted Mueller-
Hinton broth (Difco, Detroit, MI, USA) was used for sus-
ceptibility testing and IVPDM. The colony counts were
determined using tryptic soy agar (TSA) (Difco) plates.
IVPDM description
Experiments were performed in an IVPDM, as previously
described (Fig. 1).
18,19 Briefly, it was comprised of a central
compartment consisting of a dual-port 100 mL chroma-
tography column water jacket into which a dialyzer (Spec-
trum, Philadelphia, PA, USA) was suspended from a
rubber stopper. The dialyzer (peripheral compartment)
held approximately 6 mL of fluid. The dialyzer membrane
was composed of a synthetic regenerated cellulose ester
Once-Daily Gentamicin for CA-MRSA
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MATERIALS AND METHODS
Fig. 1.Schematic presentation of in vitropharmacodynamic model.with a pore size of 0.004 µm and an effective surface area-
to-volume ratio of 5.34 cm
-1. Both the central and peripheral
compartments of the model were fitted with needles for
withdrawing samples. GEN was administered via syringes
connected to the central compartment. The simulated GEN
regimens were as follows: 80 mg every 8 hours (q8h, peak
concentration 5 mg/L, half-life 2 hours) and 240 mg every
24 hours (q24h, peak concentration 15 mg/L, half-life 2
hours).
4,20 Before starting the experiment, 10 minutes pass-
ed before reaching the equilibrium of GEN concentration
between central and peripheral compartment. A total of 6
mL of bacteria (-5×10
6 CFU/mL) was injected into the
peripheral compartment after overnight incubation and
dilution of bacteria. All experiments were performed over
48 hours in triplicate for each strain. Growth controls were
also tested. 
Measurement of GEN concentrations
Pharmacokinetic samples of GEN were taken from the
central compartment at 0.25, 1, 2, 4, 6, 8, and 24 hours,
after administration and measured by fluorescence polari-
zation immunoassay (Abbott Diagnostics TDx, Irving, TX,
USA); inter-day and intra-day coefficients of variation
were less than 10% for all standards. 
Time-kill experiments and identification of SCVs
Samples for colony counts (100 µL) were taken from
peripheral compartment at 0, 1, 2, 4, 8, 24, 30, and 48 hours,
diluted in 0.9 mL of saline solution, and then plated on TSA.
The media was cultured at 37˚C for 24 hours, and the
number of colonies were measured and averaged. The lower
limit of detection was 2 log10 CFU/mL. Carryover pheno-
mena were avoided by multiple serial saline dilutions.
Bactericidal activity (99.9% kill) was defined as a ≥ 3-log10
CFU/mL reduction in colony count from the starting ino-
culum at 24 hours. Samples (100 µL) from each time point
were also plated on to TSA containing an antibiotic con-
centration of four and eight times of the MIC for each
organism and were incubated for 48 hours at 37˚C in order
to monitor the development of resistance. When resistance
was suspected, post-exposure MICs were re-evaluated.
Briefly, SCVs were identified by the following pheno-
typical characteristics: 1) slow growth, 2) small colonies,
3) decreased pigmentation, and 4) weak hemolysis on
Columbia agar (Conda, Madrid, Spain). Suspected SCVs
were also incubated with 5% CO2 over 48-72 hours. Small
colony forming S. aureus like species testing was completed
by the API ID 32 Staph system (bioMerieux Ltd, Marcy-
L’Etoile, France) and nuc gene polymerase chain reaction
(PCR).
10,19,21 
Statistical analysis
Changes in the number of colonies (log10 CFU/mL) at 24
and 48 hours were analyzed by t-test or one-way analysis
of variance with Duncan’s test using Sigma Stat version
3.10 (Systat Software, San Jose, CA, USA). Statistical
significance was defined as a p< 0.05. 
The pre-exposure MICs for YSSA1 and YSSA15 were 1
and 2 mg/L, respectively. The actual peaks were 6.4 ± 0.8
in TD and 17.2 ± 1.0 mg/L for OD dosing with measured
half-lives of 2.2 ± 0.2 hour. All simulations achieved peak
concentrations and measured half-lives were within 10% of
targeted values. Pharmacodynamic indices were shown in
Table 1. AUC0-24/MIC values were not statistically differ-
ent according to the dosing regimens in each strain. Both
strains had peak/MIC indices of more than 8.6 in OD
regimen at least. However, less values (< 6.4) of peak/MIC
were observed in TD dosing.
Colony counts at 0 hour were in the range of 6.42-6.90
log10 CFU/mL. Results of the experiments with YSSA1
and YSSA15 are presented in Fig. 2. A ≥ 3-log10 reduction
in CFU/mL was demonstrated prior to 4 hours in TD and
OD regimen for both strains and continued until 8 hours.
The slopes of bacterial killing were not different between
OD and TD regimens in both regimens during 8 hours.
Reductions in the colony counts at 24 and 48 hours were
significantly larger for OD compared to TD in both strains
(p < 0.001). For YSSA1, resistance developed with re-
growth after 24 hours during TD. The post-exposure MIC
at 24 hours was 16 mg/L, and persisted for 48 hours. For
Sun Woo Kim, et al.
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RESULTS
Table 1.Pharmacodynamic Parameter in the in vitroPharmacodynamic Model*
Drug and  Results for strain
dosing YSSA1 YSSA15
regimen T > MIC (%)
� AUC0-24  / MIC Peak / MIC T > MIC (%) AUC0-24  / MIC Peak / MIC
GEN 80 mg q8h 75.1 ± 1.0 93.8 ± 2.3 6.4 ± 0.8 49.9 ± 2.1 46.0 ± 1.8 3.2 ± 0.5
GEN 240 mg q24h 38.3 ± 0.2 93.8 ± 3.1 17.2 ± 1.0 28.8 ± 0.3 47.5 ± 2.7 8.6 ± 0.8
AUC0-24, area under the curve from 0 to 24 hours; GEN, gentamicin; q8h, every 8 hours; q24h, every 24 hours.
*All values are means ±standard deviations (n = 3).
�T > MIC, percentage of time that the drug concentration was above the MIC.OD, the bacteria were eradicated by 8 hours, and still
undetectable at the end of the experiment. For YSSA15, re-
growth of the colonies were shown beyond the 8 hours time
point and SCVs were documented starting at 30 hours of
the TD therapy with the similar number of normal colo-
nies, but none could be documented in the OD regimen for
the entire experiment. No colony was observed after eradi-
cation 4 hours during OD dosing. The SCV had a GEN
MIC greater than 512 mg/L. 
Aminolglycosides are known to concentration-dependent
killers with post-antibiotic effect (PAE) in Gram negative
organisms.
13,14 The superiority of OD aminoglycoside regi-
mens to better suppress the emergence of resistance has
been demonstrated.
22 It is also reported for GEN that the
period of PAE and adaptive resistance by several Gram
negative organisms were related to the peak concentration
of the aminoglycosides.
14,23,24 Thus, the aminoglycoside
peak concentration dependent effect on resistance, optimiz-
ed by OD dosing in contrast to more frequent dosing, has
been known. However, the relationship between concen-
tration and rate of bacterial kill or resistance development
of GEN with Gram-positive organisms such as S. aureus,
and their differences with Gram negative organisms are not
well established. 
In this experiment, although thorough dose-fractionation
studies were not completely performed, the bacterial kill-
ing rates (slope of curve) out to the 8 hours time point seem-
ed not to be different between these two regimens as previ-
ously reported.
25,26 However, OD dosing over 24-48 hours
had superior killing effects than TD as the same thing
happened in Gram negative organisms. Considering the
early rapid killing characteristics of GEN, hypotheses of
these discordances (i.e., non-concentration dependent cha-
racteristics on early phase, and then concentration depen-
dent killing) would the be rapid killing of susceptible pop-
ulations during the early period and then re-growth of
resistant subpopulations later. For further understanding of
PD characteristics of GEN against CA-MRSA, complete
dose-fractionation studies with strains of variable MICs are
warranted. 
Munckhof, et al.
6 reported that high-level resistance
developed in vitro in CA-MRSA after exposure to GEN.
After exposure to 1-64 MIC of GEN for 24 hours, all strains
developed resistance. This finding suggests that GEN
monotherapy may not be an effective treatment choice
although most CA-MRSAs are susceptible to GEN. Based
on the in vitro data, optimum bactericidal activity of ami-
noglycosides is achieved when the exposure concentration
is approximately 8-10 times the MIC against Gram nega-
tive organisms.
13,14 In addition to maximal bactericidal acti-
vity, Blaser, et al. demonstrated that the peak/MIC ratio of
8 : 1 correlated with a decrease in the selection and re-growth
of resistant subpopulations occurring during treatment with
netilmicin.
27 In contrast to other previous reports,
6,25,26 our
study had simulated the human pharmacokinetics, extend-
ed over a 48 hours period of evaluation and also identified
the development of resistance in TD with IVPDM. During
the TD dosing in YSSA1, resistance developed with re-
growth of colony after 24 hours as in previous reports.
6
However, when dosing was changed to OD, with a peak/
MIC over 8.6 at least in both CA-MRSA strains, bacterici-
dal activity was more profound after 24 hours time point
and no re-growth or resistance occurred. One of the reasons
would be the presence of longer duration of PAE in GEN
OD regimen against CA-MRSA.
14 Even though most peak/
MIC data on aminoglycosides have been associated with
Gram-negative bacteria, the results of our study suggest
clues for maximizing their efficacies against CA-MRSA.
We plan to extend the experiments to include efficacies and
the development of resistance with antibiotic combination
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Fig. 2. Time-kill curves of gentamicin against YSSA1 (A) and YSSA15 (B). The results are presented as means ±standard deviations (error bar) of colony counts (log10
CFU/mL) for measurements done in triplicate. GEN, gentamicin; q8h, every 8 hours; q24, every 24 hours; SCVs, small colony variants. 
AB
DISCUSSIONagainst MRSA. 
Optimal therapy for S. aureus SCVs has not yet been
defined.
10 GEN is not generally recommended for SCVs
because the interruption of electron transport reduces the
electrochemical gradient across the bacterial membrane,
resulting in a decreased uptake of GEN in addition to dec-
reased susceptibility when compared to the parent strain.
21
Baumert, et al. demonstrated the sensitivity of SCVs tow-
ard antibiotics known to be taken up through the electrical
potential across the cytoplasma membrane (∆Ψ), such as
aminoglycosides, dropped 10- to 30-fold when compared
to the parent strain under routine MIC determination con-
ditions.
28 However, Park, et al. recently reported that OD
dosing of arbekacin could reduce or eliminate the appe-
arance of SCVs in IVPDM.
19 In this study, SCVs appeared
after 30 hours during TD treatment of GEN in YSSA15.
They seemed to be selected by the slow-growing subpo-
pulations. However, similar findings were not observed in
OD. Gavalda, et al. showed that ceftriaxone plus genta-
micin, both administered once a day, may be useful for
selected cases of staphylococcal endocarditis.
29 Further
studies are warranted to determine whether OD or higher
dose treatment could overcome the reduced uptake of GEN
in SCVs of S. aureus, and to determine the beneficial period
of the OD effects. This should be applied to the combi-
nation strategy with glycopeptide and aminoglycoside.
In conclusion, even if CA-MRSA is susceptible to GEN,
traditional TD dosing could be less effective and induce
resistance or SCVs during the 48 hours of the experiments.
Although peak/MIC of GEN seemed not to be associated
with better efficacies against GEN-susceptible CA-MRSA
in the earlier period (- 8 hours), peak/MIC values more than
8.6 less from the OD regimen would have advantages of
more killing effect with overcoming the emergence of resis-
tance or SCVs of CA-MRSA during the later period (≥24 to
48 hours).
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